Goldman Sachs analysts removed Amgen (AMGN) from the firm’s US Conviction List as part of its monthly update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMGN:
- Amgen price target lowered to $330 from $360 at RBC Capital
- Dow Jones Slips as Amgen and Intel Drag It Down
- Viking’s VK2735 outpacing Amgen’s MariTide, says H.C. Wainwright
- Amgen (NASDAQ:AMGN) Sinks despite Positive MariTide Trial Data
- Weight loss drugmakers in spotlight as White House proposes coverage
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
